Global Gene Therapy Market: Global Size, Trends, Competitive, And Historical & Forecast Analysis, 2022-2028: Increasing innovations & research activities, a strong product pipeline, and a rising in the prevalence of chronic disorders are some of the major factors driving the growth of the Global Gene Therapy Market.
Global Gene Therapy Market is valued at USD 3.56 Billion in 2021 and is expected to reach USD 42.3 Billion by 2028 with a CAGR of 31.48% over the forecast period.
A gene is a functioning hereditary unit of life that contains a set of instructions for performing a certain function. Gene therapy is a cutting-edge treatment for chronic illness, cancer, blood problems, and infectious disease. Gene therapy involves the replacement of faulty genes in a person's blood with good ones in order to cure or prevent disease progression. Somatic gene therapy and germline gene therapy are the two forms of gene therapy depending on the location of the gene encoding on a chromosome. It has the potential to cure a variety of disorders, including hemophilia, Parkinson's, Alzheimer's, cystic fibrosis, cancer, brain tumors, SCID, AIDS, and others. Biological vectors such as viruses, liposomes, and plasmids deliver the gene to the host cell. These vectors are further divided into two types: viral vectors and non-viral vectors. Retroviruses, lentiviruses, adenoviruses, and adeno-associated vectors make up the viral vector. Liposomes, transposons, and plasmids are examples of non-viral vectors. Physical techniques for gene transfer include electroporation, ultrasound - assisted, gene gun, and photoporation.
According to numerous accounts, the coronavirus pandemic has had no substantial influence on the selling of gene therapy drugs. The greatest influence, however, may be seen in the current research in this sector. According to Wilson Brayan, head of the FDA's Office of Tissues and Advanced Therapy, there has been no rise in the use of novel medications in gene treatments. However, he claims that because of the epidemic, authorities are prioritizing coronavirus-related findings and approvals. This might have an influence on the reaction of gene therapy Investigational New Drug applications submitted to the US Food and Drug Administration (FDA). The US FDA expert also notes that cell treatments are being researched to find a cure for coronavirus, but the rate of success of the therapy is unknown.
The global Gene Therapy market is segmented based on the vector type, delivery method, gene type, application, and region & country level. Based on vector type, the global Gene Therapy market is segmented into viral and non-viral. By delivery method, the market is segmented into in vivo and ex vivo. By gene type, the global Gene Therapy market is segmented into cytokine, antigen, suicide, tumor suppressor, receptors, deficiency, and others. By application, the global Gene Therapy market is segmented into rare diseases, oncological disorders, neurological disorders, cardiovascular diseases, infectious diseases, and others.
The regions covered in the global Gene Therapy market report are North America, Europe, Asia-Pacific, Latin America, and the rest of the World. Based on country level, the market of global Gene Therapy is sub divided into U.S., Mexico, Canada, U.K., France, Germany, China, Italy, India, Japan, Southeast Asia, Middle East Asia (Saudi Arabia, UAE, Egypt) GCC, Africa, etc.
Some major key players for the global Gene Therapy market report cover prominent players like -
One of the most recent therapeutic options in the medical field is gene therapy. It has shown encouraging outcomes in the treatment of cancer and other hereditary illnesses. As a consequence, during the last several years, gene therapy research has received more attention. Additionally, many businesses introduce cutting-edge items in an effort to capitalize on market growth potential. For instance, the National Heart, Lung, and Blood Institute awarded a scientist at the Indiana University School of Medicine USD 12 million in March 2022. The money will be used to investigate key ideas in a gene therapy strategy for more effective and possibly curative hemophilia therapies.
For biotechnology and pharmaceutical businesses, gene therapy represents a prospective sector for income generating. To take advantage of the market potential prospects for gene therapy, the majority of the leading companies are now concentrating on innovative gene therapy products. While some of these products are now in the pre-clinical stage, others are already in the clinical stage and are anticipated to get approval in the next years. Achromatopsia, Fabry disease, multiple myeloma, mucopolysaccharidosis type II, wet age-related macular degeneration, and omnithine transcarbamylase (OTC) deficiency are among the diseases that businesses in the gene therapy sector are concentrating on. As a consequence, it is anticipated that the patient pool for gene therapy would grow in the next years.
Rare genetic illnesses are becoming more common among people all over the world. The National Organization for Rare Diseases (NORD) estimates that 1 in 10,000 live births in the United States occur each year due to spinal muscular atrophy. The profession has seen technological developments that have made it easier to cure illnesses that were formerly thought to be incurable. On the other hand, one of the most common illnesses in the world is cancer. The WHO and Globocan have estimated that there are around 43 million new cases of cancer worldwide every five years. These gene treatments assist individuals who are especially susceptible to developing the condition due to genetic mutations handed down from the previous generations in preventing specific forms of cancer.
Despite the fact that cancer and SMA are becoming more common, the available treatments are quite costly. The technique is primarily promoted as a single dosage treatment plan that corrects the patient's body's hereditary malfunction. A single dosage of the cancer treatment medicine Kymriah, which costs an astounding USD 475,000, according to Novartis AG. In Japan, the identical medication costs USD 306,000.
Geographically, North America is anticipated to rule the worldwide market for gene therapy throughout the anticipated period. Several government entities are investing in the area because it has a solid regulatory environment that supports the research of cellular therapy and is home to a sizable number of biopharma firms. In turn, this is fueling the expansion of the local market.
The market in North America is projected to continue to be driven by the existence of centers and institutes working on gene treatments for research and development.
On December 8th, 2022; Emmes, a worldwide, full-service Clinical Research Organization (CRO) devoted to the development of public health and biopharma advancement, announced the establishment of a devoted cell and gene therapy research facility to expand Emmes' legacy and depth in gene and cell therapy research. The new center will serve our customers who are researching cell and gene treatments all around the globe and in a variety of therapeutic areas, including oncology, hematology, ophthalmology, and cardiology, as well as uncommon disorders. The center will bring together a team of 100 scientists to leverage on the company's 35 years of expertise in gene and cell therapy.
On November 22nd, 2022; Hemgenix (etranacogene dezaparvovec), a corresponding author virus vector-based gene therapy, has been approved by the US Food and Drug Administration for the care of adults with Hemophilia B (congenital Factor IX deficiency) who are currently undergoing the Factor IX prophylaxis treatment, have a historical or current life-threatening blood clot, or have repeated, severe spontaneous bleeding episodes.
On August 18th, 2022; bluebird bio, Inc. announced that the FDA has approved ZYNTEGLO, also recognized as beti-cel, a one-time gene therapy specifically created to cure the underlying genetic basis of beta-thalassemia in adults and children who require constant red blood cell (RBC) transfusions.
|2018 - 2021
|2022 - 2029
|Market Size in 2021:
|USD 3.56 Billion
|Base year considered
|Forecast Period CAGR %:
|Market Size Expected in 2028:
|USD 42.3 Billion
|Tables, Charts & Figures:
Audentes Therapeutic, AveXis, Inc., BioMarin Pharmaceutical Inc., Bluebird Bio, Inc., Gilead Sciences, Inc., Homology Medicines, Inc., Krystal Biotech, Inc., Novartis AG, Orchard , herapeutics PLC, Pfizer Inc., Regenxbio Inc., Rocket Pharmaceuticals, Inc., Sangamo Therapeutics, Inc., Spark Therapeutics, Inc., UniQure N.V., Others.
|By Vector Type, By Delivery Method, By Gene Type, By Application
|North America, U.S., Mexico, Canada, Europe, UK, France, Germany, Italy, Asia Pacific, China, Japan, India, Southeast Asia, South America, Brazil, Argentina, Columbia, The Middle East and Africa, GCC, Africa, Rest of the Middle East and Africa.
We are always looking to hire talented individuals with equal and extraordinary proportions of industry expertise, problem solving ability and inclination interested? please email us email@example.comJOIN US
BrandEssence® Market Research and Consulting Pvt ltd.
124, City Road, London EC1V 2NX
© Copyright 2024-25 BrandEssence® Market Research and Consulting Pvt ltd. All Rights Reserved | Designed by BrandEssence®